



Histopathological analysis of placentas with congenital cytomegalovirus infection

Uenaka, Mizuki ; Morizane, Mayumi ; Tanimura, Kenji ; Deguchi, Masashi ; Kanzawa, Maki ; Itoh, Tomoo ; Yamada, Hideto

(Citation)

Placenta, 75:62-67

(Issue Date)

2019-01

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2019 Elsevier.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

(URL)

<https://hdl.handle.net/20.500.14094/90005713>



Histopathological analysis of placentas with congenital cytomegalovirus infection

Mizuki Uenaka,¹ Mayumi Morizane,¹ Kenji Tanimura,¹ Masashi Deguchi,¹ Maki
Kanzawa,² Tomoo Itoh,² Hideto Yamada¹

¹Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine,
Kobe, Japan

²Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe,
Japan

Corresponding author: Hideto Yamada, MD, PhD, Professor & Chairman

Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine,
7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan

Tel: +81-78-382-6000 Fax: +81-78-382-6019

E-mail: yhideto@med.kobe-u.ac.jp

19 **Abstract**

20 *Introduction:* Cytomegalovirus (CMV) infection is the most common cause of congenital
21 viral infections in humans. The unusual structure of the placenta plays a pivotal role in
22 CMV transmission from mothers to fetuses. The aim of this study was to evaluate the
23 histopathological findings of placentas with congenital CMV infections.

24 *Methods:* We obtained placental specimens from 35 women who had newborns with
25 congenital CMV infections. Placental specimens, extraplacental membranes, and umbilical
26 cords were stained with hematoxylin and eosin, and subjected to immunohistochemical
27 analysis. We evaluated the localization of CMV-infected cells and other histological
28 parameters.

29 *Results:* Thirty (86%) of the 35 placentas tested positive for CMV-infected cell proteins by
30 immunohistochemistry. A majority of CMV-positive cells were present in fibroblasts and
31 endothelial cells in the villi. The number of CMV-infected cells was inversely correlated to
32 gestational age at delivery. The frequency of chronic villitis (65% vs. 11%; $p<0.01$) and
33 changes of the villi (38% vs. 0%; $p<0.05$) in the placentas from mothers with symptomatic
34 congenital CMV infections was higher than those observed in samples from mothers with
35 asymptomatic congenital infections. The frequency of changes of the decidua (43% vs. 5%;

36 p<0.01) in the placentas from mothers with non-primary CMV infections was higher than
37 those from mothers with primary infections.

38 *Discussion:* Chronic villitis and changes of the villi were associated with symptomatic
39 congenital CMV infections. The changes of the decidua were associated with congenital
40 CMV infections, in mothers with non-primary CMV infections.

41

42 **Key words:** congenital infection; cytomegalovirus; immunohistochemistry; pathology;
43 placenta

44

45 **Introduction**

46 Human cytomegalovirus (CMV) is one of the most common congenital infections
47 worldwide, and can lead to permanent disabilities. The prevalence of congenital CMV
48 infection is 0.2%–2.0% in newborns [1], and 10%–15% of infected newborns have
49 symptomatic CMV infections. Symptomatic infants can have microcephaly, neurological
50 deficiencies, hearing loss, retinopathy, and fetal growth restriction (FGR). In addition,
51 10%–15% of initially asymptomatic infants will develop long-term sequelae, including
52 sensorineural hearing loss and mental retardation [2].

53 The placenta is the major route of the mother-to-fetus transmission, in which
54 CMV spreads during maternal viremia [3]. The other route of placental infection is
55 ascending infections from the genital tract. Alternatively, CMV may reactivate from
56 latently infected cells in the pregnant uterus. Circumstantial evidence for ascending CMV
57 infection includes high rates of bacterial vaginosis [4].

58 CMV infections interfere with robust placental development, central to the
59 maintenance of a healthy pregnancy [5]. In the pregnant uterus, initial infection of the
60 uterine vasculature spreads to extravillous trophoblast [6]. CMV replicates in underlying
61 cytotrophoblast, causing a focal infection that spreads to the villous stroma and fetal
62 capillaries. CMV replication at the uterine-placental interface could impair vascular

remodeling and cause fibrosis, occluding blood flow and further reducing the exchange between the maternal and fetal circulation [7]. CMV infection of the placenta and subsequent placental dysfunction can also lead to fetal injuries. Infected placentas are either large and pale or small and fibrotic. Important microscopic findings include prominent villous fibrosis and mineralization, plasma cell infiltrates in the villous stroma, and large intranuclear inclusions with or without smaller basophilic cytoplasmic inclusions [8]. In addition, changes of amniotic membranes are observed in symptomatic CMV infections [9].

Placental factors that determine transmission to the fetus and the risk of adverse outcomes are not yet fully understood. The aim of this study was to evaluate the histopathological findings of placentas with congenital CMV infections.

Materials and Methods

Participants and diagnosis of congenital infections

Between October 2009 and July 2018, all pregnant women who visited, or were referred to, Kobe University Hospital underwent maternal serological CMV screening. The institutional review board at Kobe University Hospital approved the study, and written informed consent was obtained from all participants. These women underwent initial blood screening for CMV IgG before 22 weeks of gestation. All CMV IgG-positive women were

tested for serum CMV IgM levels and IgG avidity index (AI) 2–4 weeks after the initial CMV IgG measurements. Pregnant women who were referred after 22 weeks of gestation received simultaneous CMV IgM, IgG, and IgG avidity testing at their first visits. CMV IgG negative women received an educational intervention that focused on preventing primary infections, followed by repeat measurement of CMV IgG levels at 34–36 weeks of gestation. CMV IgG seroconversion in IgG negative women was regarded as a primary CMV infection during pregnancy. And in this study, women who had an AI <40% and a positive result for CMV IgM were considered to have primary CMV infections during pregnancy. Non-primary CMV infection was defined as a negative result for CMV IgM or a positive result for CMV IgM with an AI \geq 40% in the blood.

Serological tests for CMV-specific IgG (negative: <230, borderline: 230–240, and positive: >240) were performed using the Enzygnost assay (Siemens Healthcare Diagnostics, Tokyo, Japan). CMV-specific IgM (negative: <0.8, borderline: 0.8–1.2, and positive: >1.2 index) was measured using enzyme immunoassay kits produced by Denka Seiken (Tokyo, Japan). CMV-specific IgG avidity was measured, as described previously (Aisenkai Nichinan Hospital, Miyazaki, Japan) [10].

Urine samples were collected from newborns onto filter paper within 1 week of birth and the presence of CMV-DNA was assessed in the neonatal CMV universal

screening. Liquid urine samples were obtained from CMV-positive newborns, and the CMV-DNA copy number was determined using real-time quantitative PCR. In cases of still birth, induced abortion, and neonatal death, amniotic fluid or umbilical cord blood samples were collected. The presence of a congenital CMV infection was confirmed by positive PCR results for CMV-DNA in the liquid urine of the newborns, amniotic fluid, or umbilical cord blood samples. All newborns with positive PCR results for CMV-DNA received a workup to identify the symptoms of congenital CMV infection. Symptomatic congenital CMV infection was diagnosed when newborns with positive PCR results had microcephaly, hepatosplenomegaly/hepatitis, thrombocytopenia, abnormality of brain images, CMV-associated retinopathy, abnormal auditory brain-stem response, or were classified as small-for-gestational age (SGA) [11, 12].

Histochemical Staining of the Placentas

We examined placental specimens (one central and two to four peripheral sections). Extraplacental membranes from the ruptured edge to the placental margin, and umbilical cords from 35 pregnancies were fixed in 10% formalin (24 to 48 hours), embedded in paraffin, and sectioned for histological and immunohistochemical analysis.

Serial sections (5 µm thick) were either stained with hematoxylin and eosin or subjected to immunohistochemical staining.

Immunohistochemical staining for CMV immediate early 1 and 2 proteins (UL123) and DNA-binding protein (UL44) (clones CCH2 + DDG9, Dako, dilution 1:100) was performed in order to identify CMV-positive cells. Immunostaining was performed using a Bond Max autostainer (Leica Microsystems, Wetzlar, Germany) according to the manufacturer's instructions. Purified IgG to cellular proteins were purchased from the following sources: CD31, endothelial cells (mouse monoclonal antibody, clone JC70A, Dako); CD45, lymphocytes and monocytes (mouse monoclonal antibody, clone 2B11 + PD7/26, Dako); CD68, macrophage/dendritic cells (mouse monoclonal antibody, dilution 1:150, Dako); α -SMA, fibroblasts (mouse monoclonal antibody, clone 1A4, Dako); and Cytokeratin, epithelial cells and trophoblast (mouse monoclonal antibody, clone AE1/3, dilution 1:5, Dako). For double immunolabeling, CD31, CD45, CD68, α -SMA and cytokeratin were visualized using the Bond Polymer Refine Detection kit (Leica) in brown, while CMV was visualized with perma blue/AP (Diagnostic BioSystems, Pleasanton, CA, USA) in blue with a kernechtrot counterstain. In order to confirm that there was no difference in number of CMV-infected cells depending on the antibodies, we stained CMV-infected cells with another anti-CMV antibody (mouse monoclonal antibodies,

cocktail of clones 8B1.2, 1G5.2, 2D4.2, Merck Millipore MAB8121), which reacted with immediate early, early, and late antigen preparations in 7 cases.

To examine the alterations of villous basement membrane, periodic acid-methenamine-silver staining (PAM staining) was performed.

Histological Examination

According to the literature [13-17], 10 parameters were analyzed. Histological findings of placental lesions associated with congenital CMV infection were defined as shown in Table 1. We evaluated the number of CMV-positive cells with immunohistochemistry, the presence of cytomegalic cells with intranuclear inclusion with halos, chronic villitis, changes of the villi which was defined as the presence of 5 or more findings from the following: fibrin deposition, calcification, necrosis, hemosiderin deposition, villous congestion, villous edema, avascular villi, and breakdown of villi; delayed villous maturation, chorioamnionitis, funisitis, changes of the decidua (both plasma cell deciduitis and necrosis), changes of the amniotic membranes (multiple findings of irregular, loss of cell-cell junctions, cell fusion, blebbing), hypoxic findings (both increased syncytial knots and villous chorangiosis). The slides were analyzed by one pathologist (M.K.). For each slide the number of positive cells or foci was counted for the whole

specimen. For each placental feature, we judged it as positive if at least one slide produced findings.

Statistical Analysis

We compared the clinical and pathological findings of placentas between participants with symptomatic and asymptomatic congenital CMV infections, between symptomatic fetuses who were hyperimmunoglobulin (HIG)-treated and untreated, between mothers with primary CMV infections and non-primary infections, and between those who delivered before 32 weeks and after 32 weeks of gestation.

Between-group differences were analyzed using the Mann–Whitney *U* test, Fisher’s exact test, and the Chi-square test. Statistical significance was considered present at *p*-values less than 0.05. All statistical analyses were performed using SAS version 9.1 software (SAS Institute Inc., Cary, NC, USA).

Results

Thirty-seven women had newborns with congenital CMV infections during the study period. We obtained placental specimens from 35 of the 37 women. The other 2 women who had newborns with congenital CMV infections produced negative tests for

170 CMV IgM and high AI, and their placental specimens were not preserved at delivery.
171 Twenty-six newborns had symptomatic congenital CMV infections. HIG fetal therapies
172 were performed on 12 women with symptomatic congenital infections. The institutional
173 review board at Kobe University Hospital approved the study, and written informed consent
174 was obtained from all participants. HIG administration methods consisted of HIG injection
175 into the peritoneal cavities of affected fetuses, and intravenous HIG injections into the
176 maternal blood.

177 The clinical characteristics of 35 pregnancies with congenital CMV infections are
178 shown in Table 2. Pregnancy outcomes included 28 live births, 3 neonatal deaths, 1
179 stillbirth at 23 weeks of gestation, and 3 elective pregnancy terminations at 21 weeks of
180 gestation. The birth weight of newborns with symptomatic congenital CMV infections was
181 less than that of newborns with asymptomatic congenital CMV infections ($p<0.05$). There
182 were no statistical differences in the clinical characteristics of pregnancies in mothers with
183 primary CMV infections and those with non-primary infections.

184 Thirty (86%) of 35 placentas from pregnancies with congenital CMV infections
185 tested positive for CMV-infected-cell proteins by immunohistochemistry. The median
186 number of CMV-positive cells per specimen was 1.7 (range 0–514). We detected

CMV-infected-cell proteins on the villi of the placenta (n = 29), the amniotic membrane (n = 8), the decidua (n = 1), and the chorion (n = 1) (Fig. 1-A, B, C, D).

To determine cell types with CMV infection, double immunohistochemical staining was performed on 5 placentas in which more than 100 CMV-positive cells per one specimen (Fig. 2). The total number of CMV-positive cells in the villi of 5 placentas was 1542, and cell types with CMV infection could be determined in 549 (36%) cells by immunohistochemical staining using specific cell markers. The cell types were as follows: fibroblasts (54%), endothelial cells (31%), macrophage/dendritic cells (8%), lymphocytes/monocytes (4%), and trophoblast (3%).

Double immunohistochemical staining using specific cell markers was also performed on the extraplacental membranes including the amniotic membrane, chorion, and decidua. The total number of CMV-positive cells in the amniotic membrane of 8 placentas was 99, and the localization of CMV-positive cells was as follows: amniotic connective tissue (97%) and amniotic epithelial cells (3%). Fibroblasts of 7/74 (9%) in the amniotic connective tissue and fibroblasts of 2/7 (29%) in the chorion was infected. Endometrial glandular epithelial cells (5/5; 100%) were found to be CMV-positive in the decidua.

The number of CMV-infected cells was inversely correlated to gestational age at delivery ($r = -0.68$, $p < 0.001$) (Fig. 3). There were significantly more CMV-infected cells in

the 10 placentas obtained before 32 weeks of gestation (median 61.4, range 1–514) than there were in the 25 placentas delivered after 32 weeks of gestation (median 0.85, range 0–24.3; $p < 0.001$). There was no difference in number of CMV-infected cells, regardless of gestational age at delivery, between the two antibodies.

Table 3 shows the results of regression analyses of histological findings of placental lesions associated with congenital CMV infections. The breakdown of the villous basement membrane was detected using PAM staining (Fig. 1-E).

The frequencies of chronic villitis (65% vs. 11%; $p < 0.01$) and changes of the villi (38% vs. 0%; $p < 0.05$) were higher in the placentas from mothers with symptomatic congenital CMV infections than from those with asymptomatic infections. Although not significant, the frequency of chorioamnionitis (35% vs. 0%; $p = 0.07$) and hypoxic findings (35% vs. 0%; $p = 0.07$) were higher in the placentas from mothers with symptomatic CMV infections than from those with asymptomatic infections. Only one placenta from a mother who had asymptomatic congenital CMV infection was found to be normal. The frequency of changes in the decidua (Fig. 1-F) (43% vs. 5%; $p < 0.01$) in placentas from mothers with non-primary CMV infections was higher than those from mothers with primary infections. There were no significant differences in pathological findings between the HIG treated group and the non-treated group for symptomatic congenital CMV infections (Table 4).

223

224 **Discussion**

225 The present study found that CMV-infected cells were mainly fibroblasts and
226 endothelial cells in the villi; and some were macrophages, lymphocytes, and trophoblast. A
227 few CMV-infected cells were detected in the decidua. The frequencies of chronic villitis
228 and changes of the villi in mothers with symptomatic congenital CMV infections were
229 higher than those in mothers with asymptomatic congenital infections. These results were
230 consistent with previous studies [7, 15]. The present study for the first time demonstrated
231 that the frequency of changes of the decidua in mothers with non-primary CMV infections
232 was higher than those in mothers with primary infections; and also, for the first time
233 demonstrated that the number of CMV-infected cells was inversely correlated to gestational
234 age at delivery. Local activation of CMV might be associated with premature delivery. A
235 study of biopsy specimens from early-gestation placentas found that CMV replication
236 proteins were expressed on the epithelia of endometrial glands in the decidua and
237 cytotrophoblast in the floating villi and cell columns [4]. CMV may replicate more readily
238 in early-gestation placentas than late-gestation placentas.

239 The frequencies of chronic villitis and changes of the villi were higher in the
240 placentas from mothers with symptomatic CMV infections than from those with

241 asymptomatic infections. CMV-infected cells were detected mainly in fibroblasts and
242 endothelial cells in the villi. Endothelial fibrosis, mediated by endothelial-to-mesenchymal
243 transition (EndMT), is involved in inflammatory diseases. TNF- α , IL and TGF- β induce
244 EndMT-mediated endothelial fibrosis [18]. Activation of TGF- β 1 contributes to
245 pathological changes and may impair endothelial cell functions in villi that are chronically
246 infected with CMV [19]. CMV replication at the uterine-placental interface could impair
247 vascular remodeling and cause fibrosis, potentially occluding blood flow. These infections
248 may markedly impair placental functions, resulting in hypoxia and fetal symptoms like
249 FGR.

250 Maternal HIG treatment may suppress CMV replication in the placenta and
251 prevent placental dysfunction [7]. Of those with symptomatic congenital infections, there
252 were no significant differences in the histopathological findings between the HIG treated
253 and the non-treated groups. This result was in agreement with a recent report in which HIG
254 was not able to reduce placental viral load or histological damage [20].

255 Lymphocytes are normal constituents of the decidua, but plasma cells are not. The
256 presence of plasma cells in the decidua reflects abnormal immune environments, including
257 hematogenous infections (i.e., CMV, herpes simplex virus, syphilis) [17]. Generally,
258 plasma cell deciduitis presents in 5% of all placentas, gradually decreasing as gestational

age increases [8]. Laminar decidual necrosis may represent a physiologic change in preparation for parturition, so it may be normal at term but pathologic during the preterm period. In the present study, the frequency of changes of the decidua, including both plasma cell deciduitis and necrosis, was found to be 20%. Furthermore, the frequency of changes in the decidua was higher in placentas from mothers with non-primary CMV infections than from those with primary infections. Recently, we reported that threatened premature delivery was associated with the occurrence of congenital CMV infections in pregnant women with non-primary CMV infections, the pathophysiology of which may be closely associated with CMV reactivation during pregnancy [21]. Threatened premature delivery may reflect the inflammatory conditions in which CMV is reactivated; alternatively, it may cause CMV reactivation in pregnant women. Latently infected cells can reactivate CMV as a component of the inflammatory response to pathogenic bacteria within the pregnant uterus [4]. Physical stimulation, bleeding and bacterial infections in the decidua (i.e., the fetomaternal interface) may activate the latent virus in the uterus, and subsequently cause congenital CMV infections of fetuses in pregnant women with non-primary CMV infections.

Figure legends

277 Figure 1. (A) CMV-infected cells in villi (immunohistolochemical staining). (B)
 278 CMV-infected cells in amniotic connective tissue (immunohistological staining). (C)
 279 CMV-infected cells in chorion (immunohistological staining). (D) CMV-infected cells in
 280 decidua (immunohistological staining). (E) Breakdown of villous basement membrane
 281 (arrow). CMV-infected cells, chronic villitis, and fibrin deposition are present (periodic
 282 acid-methenamine-silver stain). (F) Plasma cell deciduitis and necrosis in decidua. Inset
 283 shows high power view for plasma cell (hematoxylin-eosin).
 284
 285 Figure 2. (A) Cytomegalic cells with intranuclear inclusion with halos (arrows) in villi
 286 (hematoxylin-eosin). (B–F) Double immunohistochemical staining of the villi. (B) Serial
 287 section of A. CMV-infected cells (blue) expressed in α -SMA (brown). (C) CMV-infected
 288 cells (blue) expressed in CD31 (brown). (D) CMV-infected cells (blue) expressed in CD45
 289 (brown). (E) CMV-infected cells (blue) expressed in CD68 (brown). (F) CMV-infected
 290 cells (blue) expressed in cytokeratin (brown).
 291
 292 Figure 3. Correlation between the number of CMV-positive cells and gestational age at
 293 delivery. Data from placentas with symptomatic congenital CMV infection and maternal
 294 primary infections (n=13) (closed circles), symptomatic CMV infection and maternal

non-primary infection (n=13) (closed triangles), asymptomatic CMV infection and maternal primary infection (n=8) (open circles), and asymptomatic CMV infection and maternal non-primary infection (n=1) (open triangles). A solid line indicates an approximately correlation between the two parameters.

Acknowledgements

We acknowledge and thank Ryuko Tsukamoto at Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, for supporting us with immunohistochemical staining.

Funding sources

This work was supported by the Ministry of Health, Labour and Welfare of Japan (grant nos. H23-Jisedai-Ippan-001, AM55708030).

Conflicts of interest

The authors report no conflict of interest.

313 **Declarations of interest**

314 None.

315

316

317 **References**

318 [1] A. Kenneson, M.J. Cannon, Review and meta-analysis of the epidemiology of
319 congenital cytomegalovirus (CMV) infection, *Rev. Med. Virol.* 17(4) (2007)
320 253-76.

321 [2] S.C. Dollard, S.D. Grosse, D.S. Ross, New estimates of the prevalence of
322 neurological and sensory sequelae and mortality associated with congenital
323 cytomegalovirus infection, *Rev. Med. Virol.* 17(5) (2007) 355-63.

324 [3] L. Pereira, E. Maidji, S. McDonagh, T. Tabata, Insights into viral
325 transmission at the uterine-placental interface, *Trends Microbiol.* 13(4) (2005)
326 164-74.

327 [4] L. Pereira, E. Maidji, S. McDonagh, O. Genbacev, S. Fisher, Human
328 cytomegalovirus transmission from the uterus to the placenta correlates with
329 the presence of pathogenic bacteria and maternal immunity, *J. Virol.* 77(24)
330 (2003) 13301-14.

331 [5] L. Pereira, T. Tabata, M. Petitt, J. Fang-Hoover, Congenital cytomegalovirus
332 infection undermines early development and functions of the human placenta,
333 Placenta 59 Suppl 1 (2017) S8-s16.

334 [6] E. Maidji, E. Percivalle, G. Gerna, S. Fisher, L. Pereira, Transmission of
335 human cytomegalovirus from infected uterine microvascular endothelial cells to
336 differentiating/invasive placental cytotrophoblasts, Virology 304(1) (2002) 53-69.

337 [7] E. Maidji, G. Nigro, T. Tabata, S. McDonagh, N. Nozawa, S. Shiboski, S. Muci,
338 M.M. Anceschi, N. Aziz, S.P. Adler, L. Pereira, Antibody treatment promotes
339 compensation for human cytomegalovirus-induced pathogenesis and a
340 hypoxia-like condition in placentas with congenital infection, Am. J. Pathol.
341 177(3) (2010) 1298-310.

342 [8] F.T. Kraus, R.W. Redline, D.J. Gersell, D.M. Nelson, J.M. Diche, Placental
343 Pathology, American Registry of Pathology, Washington, DC, 2004.

344 [9] T. Tabata, M. Petitt, J. Fang-Hoover, M. Zydek, L. Pereira, Persistent
345 Cytomegalovirus Infection in Amniotic Membranes of the Human Placenta, Am.
346 J. Pathol. 186(11) (2016) 2970-2986.

347 [10] M. Tagawa, T. Minematsu, H. Masuzaki, T. Ishimaru, H. Moriuchi,
348 Seroepidemiological survey of cytomegalovirus infection among pregnant

349 women in Nagasaki, Japan, *Pediatr. Int.* 52(3) (2010) 459-62.

350 [11] Y. Kobayashi, I. Morioka, T. Koda, Y. Nakamachi, Y. Okazaki, Y. Noguchi, M.

351 Ogi, M. Chikahira, K. Tanimura, Y. Ebina, T. Funakoshi, M. Ohashi, K. Iijima,

352 N. Inoue, S. Kawano, H. Yamada, Low total IgM values and high

353 cytomegalovirus loads in the blood of newborns with symptomatic congenital

354 cytomegalovirus infection, *J. Perinat. Med.* 43(2) (2015) 239-43.

355 [12] K. Matsuo, I. Morioka, M. Oda, Y. Kobayashi, Y. Nakamachi, S. Kawano, M.

356 Nagasaka, T. Koda, T. Yokota, S. Morikawa, A. Miwa, A. Shibata, T. Minematsu,

357 N. Inoue, H. Yamada, K. Iijima, Quantitative evaluation of ventricular

358 dilatation using computed tomography in infants with congenital

359 cytomegalovirus infection, *Brain Dev.* 36(1) (2014) 10-5.

360 [13] T.Y. Khong, E.E. Mooney, I. Ariel, N.C. Balmus, T.K. Boyd, M.A. Brundler, H.

361 Derricott, M.J. Evans, O.M. Faye-Petersen, J.E. Gillan, A.E. Heazell, D.S. Heller,

362 S.M. Jacques, S. Keating, P. Kelehan, A. Maes, E.M. McKay, T.K. Morgan, P.G.

363 Nikkels, W.T. Parks, R.W. Redline, I. Scheimberg, M.H. Schoots, N.J. Sebire, A.

364 Timmer, G. Turowski, J.P. van der Voorn, I. van Lijnschoten, S.J. Gordijn,

365 Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop

366 Group Consensus Statement, *Arch. Pathol. Lab. Med.* 140(7) (2016) 698-713.

367 [14] R.W. Redline, Inflammatory responses in the placenta and umbilical cord,
368 Semin. Fetal Neonatal Med. 11(5) (2006) 296-301.

369 [15] L. Pereira, M. Petitt, A. Fong, M. Tsuge, T. Tabata, J. Fang-Hoover, E.
370 Maidji, M. Zydek, Y. Zhou, N. Inoue, S. Loghavi, S. Pepkowitz, L.M. Kauvar, D.
371 Ogunyemi, Intrauterine growth restriction caused by underlying congenital
372 cytomegalovirus infection, J. Infect. Dis. 209(10) (2014) 1573-84.

373 [16] G. Altshuler, Chorangiosis. An important placental sign of neonatal
374 morbidity and mortality, Arch. Pathol. Lab. Med. 108(1) (1984) 71-4.

375 [17] A. Heerema-McKenney, E.J. Popek, M.E.D. Paepe, Diagnostic pathology:
376 placenta, Philadelphia, 2015.

377 [18] L. Perez, N. Munoz-Durango, C.A. Riedel, C. Echeverria, A.M. Kalergis, C.
378 Cabello-Verrugio, F. Simon, Endothelial-to-mesenchymal transition:
379 Cytokine-mediated pathways that determine endothelial fibrosis under
380 inflammatory conditions, Cytokine Growth Factor Rev. 33 (2017) 41-54.

381 [19] T. Tabata, H. Kawakatsu, E. Maidji, T. Sakai, K. Sakai, J. Fang-Hoover, M.
382 Aiba, D. Sheppard, L. Pereira, Induction of an epithelial integrin alphavbeta6 in
383 human cytomegalovirus-infected endothelial cells leads to activation of
384 transforming growth factor-beta1 and increased collagen production, Am. J.

385 Pathol. 172(4) (2008) 1127-40.

386 [20] L. Gabrielli, M.P. Bonasoni, M.P. Foschini, E.M. Silini, A. Spinillo, M.G.
387 Revello, A. Chierighin, G. Piccirilli, E. Petrisli, G. Turello, G. Simonazzi, D.
388 Gibertoni, T. Lazzarotto, Histological Analysis of Term Placentas from
389 Hyperimmune Globulin-Treated and Untreated Mothers with Primary
390 Cytomegalovirus Infection, Fetal Diagn. Ther. (2018) 1-7.

391 [21] H. Yamada, K. Tanimura, S. Tairaku, I. Morioka, M. Deguchi, M. Morizane,
392 S. Nagamata, K. Ozaki, Y. Ebina, T. Minematsu, Clinical factor associated with
393 congenital cytomegalovirus infection in pregnant women with non-primary
394 infection, Journal of infection and chemotherapy : official journal of the Japan
395 Society of Chemotherapy (2018).

396

Table 1. The definition of histological findings of placental lesions associated with congenital cytomegalovirus infection

Parameter	Definition (findings regarded as positive)
Presence of intranuclear inclusions	(At least one cell)
Number of cytomegalovirus-positive cells	Average number per slide by immunohistochemistry
Chronic villitis	Infiltrates of lymphocytes, histiocytes, plasma cells, and eosinophils (multiple foci of villi , on multiple slides)
Changes of the villi:	
Fibrin deposition	(≥3% of villi)
Calcification	(≥5 small or ≥1 big per slide)
Necrosis	Loss of nuclear staining of the stroma (≥3% of villi)
Hemosiderin deposition	A yellowish brown granular pigment found in macrophage (at least one cell)
Villous congestion	Prominent capillaries in the villi but there is no numerical increase in the number of capillaries (multiple foci of villi)
Villous edema	(Multiple foci of villi)
Avascular villi	Terminal villi with total loss of villous capillaries and bland hyaline fibrosis of villous stroma (≥3 foci of more than 2 terminal villi)
Breakdown of villi	Breakdown of trophoblastic basement membrane (≥30% of villi)
Delayed villous maturation	Diffuse abnormality of distal villi characterized by poor vasculosyncytial membrane formation, prominent villous cytotrophoblast cellularity, and increased villous stroma (≥30% of villi)
Chorioamnionitis	Redline's criteria (Stage 2 or 3 in maternal inflammatory response)
Funisitis	Redline's criteria (Stage 1 or 2 or 3 in fetal inflammatory response)
Changes of the decidua:	
Plasma cell deciduitis	Presence of mixed plasma cells and lymphocytes in decidua basalis adjacent to maternal floor (multiple foci of decidua)
Necrosis	Loss of nuclear basophilia of decidual stromal cells and vessels in band-like pattern (multiple foci of decidua)
Changes of the amniotic membranes:	
Irregularity	Amnion cells showed columnar change (≥30% of epithelial cells in amniotic membranes)
lost of cell-cell junctions	(≥30% of epithelial cells in amniotic membranes)
Cell fusion	Amnion cells showed pseudostratified columnar (multiple foci in amniotic membranes)
Blebbing	Intracytoplasmic vacuolation (multiple foci in amniotic membranes)
Hypoxic findings:	
Increased syncytial knots	Localized aggregation of syncytiotrophoblastic nuclei in the villi [≥20% (before 34 weeks of gestation) or 30% (after 38 weeks of gestation)]
Villous chorangiosis	Altshuler's criteria (at least 10 vascular profiles per terminal/intermediate chorionic villus in 10 chorionic villi per x10 objective microscopic field in at least 10 areas of 3 or more random cotyledons)

Table 2. Clinical characteristics of 35 pregnancies with congenital cytomegalovirus infection

	All (n = 35)	Congenital cytomegalovirus infection			Maternal cytomegalovirus infection		
		Symptomatic (n = 26)	Asymptomatic (n = 9)	<i>p value</i>	Primary (n = 21)	Nonprimary (n = 14)	<i>p value</i>
Maternal age, years old	30.2 ± 5.5	30 (19-40)	29 (19-36)	0.85	29 (19-37)	33 (21-40)	0.26
Gravity	2.1 ± 1.3	2 (1-8)	2 (1-4)	0.82	2 (1-4)	2 (1-8)	0.19
Parity	0.6 ± 0.7	0 (0-2)	1 (0-3)	0.58	1 (0-3)	0 (0-2)	0.57
Gestational week at the initial AI measurements	25.4 ± 7.5	25 (16-35)	23 (12-42)	0.68	23 (12-39)	30 (16-42)	0.12
Gestational week at delivery	33.4 ± 5.7	34 (21-40)	38 (21-40)	0.13	36 (21-39)	36 (21-40)	0.67
Birth weight, g	2045.1 ± 901.4	2030 (311-3216)	2786 (410-3320)	p<0.05	2381 (311-3274)	1989 (326-3320)	0.46
Placental weight, g	467.5 ± 161.8	463 (222-950)	496 (150-574)	0.53	496 (150-796)	439 (222-950)	0.50

Data are expressed as the mean ± standard deviation, or median (range)







AI, cytomegalovirus immunoglobulin G avidity index

Table 3. Histopathological findings associated with congenital cytomegalovirus infection.

Factors	All (n = 35)	Congenital cytomegalovirus infection			Maternal cytomegalovirus infection		
		Symptomatic (n = 26)	Asymptomatic (n = 9)	<i>p value</i>	Primary (n = 21)	Nonprimary (n = 14)	<i>p value</i>
Presence of cytomegalovirus-positive cells	30 (86%)	22 (85%)	8 (89%)	1.00	19 (90%)	11 (79%)	0.37
Number of cytomegalovirus-positive cells, median (range)	1.7 (0-514)	5.6 (0-514)	1.0 (0-98)	0.26	1.7 (0-514)	1.2 (0-468)	0.41
Presence of intranuclear inclusions	19 (54%)	15 (58%)	4 (44%)	0.70	11 (52%)	8 (57%)	0.78
Chronic villitis	18 (51%)	17 (65%)	1 (11%)	p<0.01	10 (48%)	8 (57%)	0.58
Changes of the villi	10 (29%)	10 (38%)	0	p<0.05	5 (24%)	5 (36%)	0.47
Delayed villous maturation	10 (29%)	9 (35%)	1 (11%)	0.23	5 (24%)	5 (36%)	0.47
Chorioamnionitis	9 (26%)	9 (35%)	0	0.07	5 (24%)	4 (29%)	1.00
Funisitis	5 (14%)	4 (15%)	1 (11%)	1.00	3 (14%)	2 (14%)	1.00
Changes of the decidua	7 (20%)	7 (27%)	0	0.15	1 (4.8%)	6 (43%)	p<0.01
Changes of the amniotic membranes	16 (46%)	13 (50%)	3 (33%)	0.46	10 (48%)	6 (43%)	0.78
Hypoxic findings	9 (26%)	9 (35%)	0	0.07	3 (14%)	6 (43%)	0.11

Table 4. Histopathological findings associated with symptomatic congenital cytomegalovirus infection

	Hyperimmune globulin treatment (n = 12)	Non-treatment (n = 14)	<i>p value</i>
Presence of cytomegalovirus-positive cells	11 (92%)	11 (79%)	0.60
Number of cytomegalovirus-positive cells, median (range)	2.8 (0-144)	9.5 (0-514)	0.61
Presence of intranuclear inclusions	7 (58%)	8 (57%)	1.00
Chronic villitis	9 (75%)	11 (79%)	1.00
Changes of the villi	5 (42%)	5 (36%)	1.00
Delayed villous maturation	5 (42%)	4 (29%)	0.68
Chorioamnionitis	2 (17%)	7 (50%)	0.11
Funisitis	1 (8.3%)	3 (21%)	0.60
Changes of the decidua	1 (8.3%)	5 (36%)	0.39
Changes of the amniotic membranes	7 (58%)	6 (43%)	0.70
Hypoxic findings	4 (33%)	5 (36%)	1.00











Figure 3. Correlation between the number of CMV-positive cells and gestational age at delivery

